Denali Therapeutics Inc (DNLI) is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company's lead program is focused on Parkinson's disease, and it has several other programs targeting other diseases, including Alzheimer's disease, ALS, and multiple sclerosis.
Denali Therapeutics is developing a pipeline of therapeutic candidates based on its proprietary technology platform, which includes antibody and small molecule discovery platforms, as well as protein degradation technologies. Its lead program, DNL201, is a small molecule inhibitor of LRRK2, a protein kinase that has been linked to Parkinson's disease. The company is also developing a number of other small molecule inhibitors and antibodies for the treatment of neurodegenerative diseases.
Denali Therapeutics was founded in 2015 by a team of experienced biotechnology executives, including former Genentech scientists Ryan Watts and Marc Tessier-Lavigne. The company is headquartered in South San Francisco, California.
|
